SELLAS Life Sciences Group Inc

NASDAQ:SLS 4:00:00 PM EDT

1.54

-0.09 (-5.52%)

7:59:54 PM EDT: $1.56 +0.02 (+1.30%)

Market Cap (Intraday)	86.65M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$13 Million
Adjusted EPS	-$0.02

See more estimates

10-Day MA	$1.49
50-Day MA	$1.19
200-Day MA	$1.18

See more pivots

SELLAS Life Sciences Group Inc Stock, NASDAQ:SLS

Times Square Tower, 7 Times Square, New York, New York 10026

United States of America

Phone: +1.646.200.5278

Number of Employees: 16

http://www.sellaslifesciences.com

Description

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.